Cantor Fitzgerald Predicts ADMA Biologics FY2025 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ADMA Biologics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of $0.70 per share for the year. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same quarter in the prior year, the firm earned $0.01 EPS.

Several other equities analysts also recently issued reports on the stock. HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Up 0.7 %

Shares of NASDAQ ADMA opened at $16.58 on Wednesday. ADMA Biologics has a 1 year low of $5.02 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market cap of $3.92 billion, a PE ratio of 59.21 and a beta of 0.76. The company has a 50 day simple moving average of $18.69 and a 200 day simple moving average of $17.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of ADMA Biologics by 13.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after acquiring an additional 80,400 shares in the last quarter. Assenagon Asset Management S.A. increased its position in ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in ADMA Biologics during the 3rd quarter worth approximately $61,858,000. EWG Elevate Inc. bought a new position in ADMA Biologics in the fourth quarter worth approximately $480,000. Finally, Citigroup Inc. grew its stake in ADMA Biologics by 251.7% in the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after acquiring an additional 277,138 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.